Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Seres Therapeutics, Inc. Investors & E...
November 22 2016 - 11:09AM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces that a
class action lawsuit has been filed on behalf of investors who
purchased Seres Therapeutics, Inc. (“Seres” or the “Company”)
(NASDAQ: MCRB) securities between June 25, 2015 and July 29,
2016, inclusive (the “Class Period”). Seres investors have
until November 28, 2016 to file a lead plaintiff
motion.
Investors suffering losses on their Seres investments are
encouraged to contact Lesley Portnoy of GPM to discuss their legal
rights in this class action at 310-201-9150 or by email to
shareholders@glancylaw.com.
According to the complaint filed in this lawsuit, throughout the
Class Period defendants issued false and misleading statements to
investors that Seres Therapeutics advertised and hyped its lead
drug product candidate SER-109 as “novel class of biological drugs”
and a potential “first-in-field drug” despite knowledge that the
Phase 2 clinical trial of SER-109 would fail to achieve its primary
endpoint as compared to placebo. When the true details entered the
market, the lawsuit claims that investors suffered damages.
If you purchased shares of Seres during the Class Period you may
move the Court no later than November 28, 2016 to
ask the Court to appoint you as lead plaintiff if you meet certain
legal requirements. To be a member of the Class you need not take
any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you
wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Lesley Portnoy,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com, or visit our website at
http://glancylaw.com. If you inquire by email please include your
mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161122005780/en/
Glancy Prongay and Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224https://www.glancylaw.comshareholders@glancylaw.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024